Schizophrenia is a serious psychiatric disorder that develops mainly in young adults. Electroconvulsive therapy (ECT) is known to be effective and safe in patients with schizophrenia with acute psychotic exacerbation. Because of the shortage of systematic studies, we conducted a prospective naturalistic study to examine the short-term effects of acute ECT and its safety in young adults with medically intractable first-episode schizophrenia. Subjects were seven consecutive patients, 15-35 years of age, with firstepisode schizophrenia or schizophreniform disorder (Diagnostic and Statistical Manual of Mental Disorders, 4th edition; DSM-IV), who had failed to respond to neuroleptics. The seven patients were treated with a first course of ECT, and their clinical symptoms were evaluated on the basis of the Brief Psychiatric Rating Scale (BPRS) (18 items, rated 0-6) and Global Assessment of Functioning (GAF) Scale. The GAF Scale is presented in DSM-IV as a means of assessing global functioning of a psychiatric patient. Scores range from 1-100; the higher GAF score indicates the higher global functioning. Adverse effects resulting from acute ECT were also evaluated. The total BPRS score 1 week after the final session improved significantly compared to the total pre-ECT BPRS score. The GAF score also improved significantly compared to the pre-ECT GAF score. There were no adverse effects during the acute ECT course, except for mild delirium. We conclude that ECT may be an effective and safe treatment option for young adults with intractable firstepisode schizophrenia. electroconvulsive therapy; short-term effect; first-episode schizophrenia; intractable schizophrenia; young adults
Schizophrenia is a serious psychiatric disorder that develops mainly in young adults. The outcome is poor in about 10-20% of first-episode cases despite neuroleptic treatment (Sheitman et al. 1997; Vazquez-Barquero et al. 1999; Barnes et al. 2000; Lieberman et al. 2003) . The management of these poor-outcome cases is important in clinical practice. Because some symptoms of schizophrenia, for example, hallucination, delusion, loose association, and abulia, can compromise the patient's quality of life for a long time, the need for an efficacious treatment strategy for such patients is urgent.
Electroconvulsive therapy (ECT) is widely used and known to be effective and safe in patients with schizophrenia with acute psychotic exacerbation who have a limited response to neuroleptics (Kruger and Sackeim 1995; Chanpattana et al. 1999; Weiner 2001; Tharyan and Adams 2005) . Thus, some authors have speculated that ECT would be a useful treatment option for patients with first-episode schizophrenia (Kellner 1995; Fink and Sackeim 1996; Abrams 2002) . However, to our knowledge, with the exception of one seminal study (Ucok and Cakr 2006) , there have been no systematic studies on the short-term efficacy and safety of acute ECT in the treatment of young adults with medically intractable firstepisode schizophrenia. We conducted a prospective naturalistic study to examine the short-term effects of acute ECT in young adults with medically intractable first-episode schizophrenia.
METHODS

Background
Subjects of this study were young adults identified among 58 psychiatric patients referred to Tohoku University Hospital between January 1, 2000, and March 31, 2006, for first-time acute ECT. Diagnoses were mood disorder (n = 31, 53.4%), schizophrenia (n = 26, 44.8%), and somatoform disorder (n = 1, 1.7%). Our study subjects were taken from 26 patients with schizophrenia and comprised seven consecutive patients less than 35 years for age who were suffering their first episode of schizophrenia. Before the acute ECT course, all seven were evaluated with MRI of the brain, which revealed no abnormality in any subjects. The ethics committee at Tohoku University Graduate School of Medicine approved this study.
SUBJECTS AND METHODS
Subjects
The seven subjects were five males and two females with a mean ± S.D. age of 23.6 ± 6.8 years (range, 15-34 years). All met the following inclusion criteria: 1) use of acute ECT approved independently by two research psychiatrists on the ECT team; 2) fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria for schizophrenia or schizophreniform disorder (American Psychiatric Association 1994); 3) disease intractability, as described below, and marked psychopathologic symptoms (as evidenced by a Brief Psychiatric Rating Scale [BPRS] score > 35 [18 items, rated 0-6]) (Overall and Gorham 1962) ; 4) age between 15 and 35 years at the start of acute ECT; 5) written informed consent provided by the patient or guardian; 6) ECT for patients less than 18 years of age approved by the entire ECT team and one consultant experienced in treating psychiatric disorders of children and adolescents. Intractability was defined as disease resistant to medication or medication intolerance or a severe resultant medical or psychiatric condition (e.g., inanition due to refusal eat or high risk of suicide). Resistance to medication was defined as failure to achieve substantial relief of symptoms (as evidenced by a BPRS score > 35) despite the use of at least one class of neuroleptics for a period of at least 4 weeks at a dose equivalent to more than 600 mg chlorpromazine. Patients with a clinical history that included dementia or substance abuse were not included in the study.
Acute ECT
Only modified ECT was used. Atropine sulfate (0.5 mg) was administered intramuscularly, and thiopental (2-4 mg/kg) or propofol (1-1.5 mg/kg) was used as an anesthetic agent and succinylcholine (1-1.5 mg/kg) as a muscle relaxant. The ECT device used in the phase 1 study was a CS-I sine-wave apparatus (Sakai Medical Corp., Tokyo) or a Thymatron System IV brief-pulse square-wave apparatus (Somatics, LLC, Lake Bluff, USA). Electrodes were placed in the traditional bilateral fronto-temporal manner. Only one adequate seizure was required for each session, and this was defined as a cerebral seizure monitored electroencephalographically and exceeding 20 seconds. Stimulation with the CS-1 apparatus was done with an alternating current of 100 volts at 50 Hz for 5 seconds. If a missed or inadequate seizure occurred, the patient was restimulated at the same electrical dose after a 20-to 30-second pause. The maximum number of stimulation for each treatment session was three. When stimulation was done with the Thymatron System IV apparatus, the electrical dosing schedule followed stimulus dose titration (Kellner 1997) . If a missed or inadequate seizure occurred, the patient was restimulated (after a 20-to 30-second pause [for a missed seizure] or a 60-second pause [for an inadequate seizure]) at a stimulus intensity increment of 100% to obtain an adequate seizure. The maximum number of stimulations for the first treatment session was four and that for the later treatment sessions was three. ECT was administered two or three times per week, and the total number of ECT sessions in an acute ECT course was limited to 20. In general, neuroleptics were used to augment the effect of ECT during the acute ECT course. The attending physician and the ECT team selected the class and dosage of the medication on a case-by-case basis.
Clinical evaluation
Outcome in each case was determined by comparing the BPRS score obtained just before the ECT course, the score obtained at the end of the ECT course, and the score obtained 1 week after the final ECT session and by comparing the Global Assessment of Functioning (GAF) score determined just before the ECT course with that obtained 1 week after the final ECT session (American Psychiatric Association 1994). Two experienced research psychiatrists on the ECT team served as raters for these evaluations. Average scores were used. The BPRS consists of 18 items (each item rated 0-6) measuring the severity of a patient's psychiatric symptoms; the higher total BPRS score indicates the greater severity of the psychiatric symptoms. The GAF Scale is presented in the DSM-IV as a means of assessing global functioning. Scores range from 1-100; the higher GAF score indicates the higher global functioning. The Chanpattana et al. criterion, that patients were considered clinical responders if they had a BPRS score 25 for 1 week after the final ECT session, was adopted for our study (Chanpattana et al. 1999) .
Patients were also evaluated on the basis of Guy's five factors, which groups the 18 BPRS items into five subscales: thought disturbance (conceptual disorganization, grandiosity, hallucinatory behavior, unusual thought content), activation (tension, mannerisms and posturing, excitement), anxiety-depression (somatic concern, anxiety, guilt feelings, depressive mood), hostility-suspiciousness (hostility, suspiciousness, uncooperativeness), and anergia (emotional withdrawal, motor retardation, blunted affect, disorientation) (Guy 1976 ).
Adverse cognitive effects resulting from acute ECT were evaluated on the basis of the Mini Mental State Examination (MMSE), which that was administered before and 2 weeks after the acute ECT course. Adverse physical effects from acute ECT were noted in the patient's record by the attending physician. To identify any epileptic abnormality induced by ECT, electroencephalographic examination was performed before and 2 weeks after the acute ECT course. Characteristics of the study patients before ECT are shown in Tables 1, 2, and 3. Values are shown as mean ± S.D. Differences in test 
RESULTS
All seven patients completed the study. The mean number of ECT sessions was 11.3 ± 4.3 (range, 7-20 sessions). Three patients (patients 1, 2, and 6) were treated with the CS-1 apparatus and four (patients 3, 4, 5, and 7) with the Thymatron System IV brief-pulse square-wave apparatus. The mean duration of electroencephalographic cerebral seizures was 67.4 ± 37.0 seconds (range, 20-204 seconds). The mean initial and maximal stimulus charges used in the four patients treated with the Thymatron System IV apparatus were 68.9 ± 37.5 millcoulomb (mC) (range, 25.1-100.4 mC) and 175.7 ± 93.1 mC (range, 75.3-301.2 mC), respectively.
The total BPRS score at the end of the ECT course and that 1 week after the final session improved significantly in comparison to the total pre-ECT BPRS score (10.7 ± 6.6 at the end of the ECT course and 10.1 ± 7.9 1 week after the final session versus 44.4 ± 5.3 just before ECT, respectively; Z = 2.37, p = 0.018; Z = 2.37, p = 0.018).
The GAF score also improved significantly (from 18.6 ± 9.0 just before ECT to 54.3 ± 23.7 1 week after ECT; Z = 2.37, p = 0.018). All seven patients were considered ECT responders (Fig. 1) ; thus, the ECT response rate was 100%. Three of the seven patients responded completely (total BPRS score < 5). All five factors (thought disturbance, activation, anxiety-depression, hostilitysuspiciousness, and anergia) improved significantly ( p = 0.018, p = 0.018, p = 0.018, p = 0.018, and p = 0.028, respectively) ( Table 3) .
The MMSE score did not decrease after the acute ECT course in any of the five examined patients (Table 2) . After several ECT sessions, two (patients 2 and 3) of the seven patients (28.6%) exhibited mild to moderate delirium that disappeared within 1 hour. Slight to moderate slowing was recorded on the electroencephalograms (EEGs) of the five patients after the acute ECT course (Table 2) . No patient exhibited epileptic discharge on the EEG after the acute ECT course (Table 2) . No patient experienced any other adverse cognitive or physical effect during the course of acute ECT.
DISCUSSION
We studied the short-term effects and safety of acute ECT in young adults with first-episode schizophrenia or schizophreniform disorder. Both psychiatric symptoms and global functioning of Thought disturbance 12.0 ± 3.9 (5-17) 1.7 ± 2.9 (0-8) 0.018 Activation 7.6 ± 3.6 (3-13) 1.3 ± 1.6 (0-4) 0.018 Anxiety-depression 6.1 ± 2.1 (4-10) 1.3 ± 1.1 (0-3) 0.018 Hostility-suspiciousness 6.4 ± 3.0 (5-13) 0.3 ± 0.8 (0-2) 0.018 Anergia 12.3 ± 3.5 (7-17) 5.1 ± 3. these patients improved significantly with administration of acute ECT combined with neuroleptics. All seven patients responded to the acute ECT course. There were no marked adverse cognitive, physical, or electroencephalographic effects due to ECT. Thus, acute ECT may be effective and safe for young patients with medically intractable first-episode schizophrenia. Recently, Ucok and Cakr (2006) reported a good short-term effect of ECT vs neuroleptics in 13 patients with first-episode schizophrenia. Our study subjects differed from theirs in three ways. First, duration of the psychotic episode prior to the first acute ECT in our patients appeared to be longer than that reported by Ucok and Cakr (2006) . Second, there were fewer patients with catatonic type schizophrenia in our study. Third, there were more patients with medication-resistant schizophrenia in our study. All three of these factors are predictors of a poor response to acute ECT (Dodwell and Goldberg 1989; Chanpattana and Chakradhand 2001; Weiner 2001; Abrams 2002; Suzuki et al. 2003) . However, the favorable result of our study accorded well with that of the Ucok and Cakr study. One full trial of ECT appears to be warranted for patients with firstepisode schizophrenia even if factors predictive of a poor response to acute ECT are present.
Our finding that ECT may be effective for first-episode schizophrenia suggests that ECT should be considered a treatment option for firstepisode schizophrenia. The rationale is as follows: First, ECT is more effective for acute schizophrenia than for chronic schizophrenia (Dodwell and Goldberg 1989; Krueger and Sackeim 1995; Chanpattana and Chakrabhand 2001; Abrams 2002) . It may be helpful to administer ECT before the illness becomes chronic. Second, young adults are in particular need of a rapid and definitive resolution of schizophrenia. Young adulthood is a critical time for development of a balanced personality. Persistent, severe psychiatric symptoms stunt development, leading to an inability to maintain good social relationships and to stigmatization. Third, the clinical picture in first-episode psychosis is often elusive (Fennig et al. 1994) . It is sometimes difficult to distinguish schizophrenia from affective disorder. When affective disorder is mistaken for schizophrenia, administration of potent neuroleptics can cause severe side effects. However, ECT is efficacious and safe in patients with either disorder (Weiner 2001; Abrams 2002) . Further studies in large numbers of patients are needed to establish the efficacy and safety of ECT for first-episode schizophrenia. In addition, further studies pertaining to long-term outcome of the use of ECT for first-episode schizophrenia are needed.
Our study was limited by our partial use of the sine-wave ECT apparatus, the small number of subjects, and the fact that it was naturalistic. However, it was a prospective study of the efficacy and safety of ECT in young adults with medically intractable first-episode schizophrenia. We conclude that ECT may be an effective and safe treatment option for such patients. Further systematic studies on a large scale are warranted.
